Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health reported Q3 2026 revenue up 70% year over year to $5.1 billion, net income of $167.3 million versus a $137.5 million loss a year earlier, and a 450-basis-point improvement in its medical loss ratio to 84.0%. The company raised 2026 operating earnings guidance for the third time to $850 million-$950 million, with revenue guidance of $19.0 billion-$19.3 billion; management cited favorable risk adjustment and moderately favorable utilization. Membership rose 27% to 2.7 million, while management expects about 2.5 million members at year-end after additional CMS-related disenrollments and anticipates a roughly 14% weighted-average rate increase for 2027.

Analysis

The headline earnings improvement is less durable than the guidance increase implies: a $250m risk-adjustment benefit and favorable utilization are doing meaningful work, while the Q4 outlook itself anticipates a seasonal MLR step-up. The key underwriting test is whether 2027 pricing—whose largest stated component is high-single-digit medical trend—covers claims inflation and worsening morbidity without sacrificing enrollment to cheaper competitors. Broker verification friction and further CMS reviews can hurt near-term conversion; competitor exits offer share opportunity, but share is valuable only if Oscar retains pricing discipline.

Do not treat Lucie’s 800,000 policy target as 800,000 Oscar members or equivalent underwriting revenue: the platform places consumers with other carriers too. It could create distribution economics and broker stickiness, but also funnel applicants away from Oscar; fees, conversion, retention, and carrier mix are unreported. The Allstate Corporation (ALL) partnership likewise has no disclosed economics to support a material earnings read-through.

Major source-quality issue: the transcript claims $1.3bn of nine-month operating earnings, which does not reconcile with the stated $850–950m full-year guidance; verify the 10-Q and earnings release before sizing any position. Near term, enrollment conversion and CMS processing are the catalysts. Over 6–18 months, policy/subsidy changes and whether risk-adjustment gains recur dominate. The contrarian point: strong reported growth may be masking dependence on a favorable risk-score true-up, while platform scale and long-term EPS targets remain unproven financially.

Key Decisions for Investors

• No immediate directional trade until the nine-month earnings/guidance discrepancy is reconciled against Oscar Health, Inc. (OSCR)’s SEC filing. If confirmed as a transcript error and open-enrollment indicators remain sound, consider a small, defined-risk OSCR call spread rather than unhedged exposure; do not price in the long-term EPS target as a near-term catalyst.
• Track weekly enrollment and broker productivity, CMS disenrollments, and 2027 member mix. Falsify the share-gain thesis if enrollment friction or competitor underpricing produces weaker-than-expected conversion, or if Oscar must discount to defend share.
• Monitor risk-adjustment accruals and MLR separately from underlying claims trend. A reversal in risk-score relative performance, worse outpatient claims, or a 2027 MLR outlook that absorbs the pricing increase would undermine the earnings-quality thesis.
• Treat Lucie and the ALL partnership as watch items, not current earnings drivers: seek disclosed platform fees, Oscar-plan conversion/retention, and incremental ALL economics before assigning material value.